Stem Cells http://www.stemcellsportal.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online May 3, 2007
Stem Cells Vol. 25 No. 8 August 2007, pp. 2118 -2127
doi:10.1634/stemcells.2006-0771; www.StemCells.com
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
2006-0771v1
25/8/2118    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, W.
Right arrow Articles by Steinhoff, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, W.
Right arrow Articles by Steinhoff, G.

TRANSLATIONAL AND CLINICAL RESEARCH: MESENCHYMAL STEM CELLS SERIES

Bcl-2 Engineered MSCs Inhibited Apoptosis and Improved Heart Function

Wenzhong Lia, Nan Maa, Lee-Lee Onga, Catharina Nesselmanna, Christian Klopscha, Yury Ladilova, Dario Furlania, Christoph Piechaczekb, Jeannette M. Moebiusb, Karola Lützowc, Andreas Lendleinc, Christof Stammd, Ren-Ke Lie, Gustav Steinhoffa

aDepartment of Cardiac Surgery, University of Rostock, Rostock, Germany;
bMiltenyi Biotec, Bergisch Gladbach, Germany;
cInstitute of Polymer Research, GKSS Forschungszentrum, Teltow, Germany;
dCardiac Surgery, German Heart Institute Berlin, Berlin, Germany;
eDivisions of Cardiovascular Surgery and Cardiology, Toronto General Hospital and the University of Toronto, Toronto, Ontario, Canada

Key Words. Gene therapy • Stem cells • Transplantation • Angiogenesis • Antiapoptosis

Correspondence: Nan Ma, M.D., Ph.D., Department of Cardiac Surgery, University Rostock, Schillingallee 69, 18057 Rostock, Germany. Telephone: +49-381-494 6105; Fax: +49-381-494 6214; e-mail: nan.ma{at}med.uni-rostock.de

Received November 24, 2006; accepted for publication April 20, 2007.
First published online in STEM CELLS EXPRESS   May 3, 2007.



Engraftment of mesenchymal stem cells (MSCs) derived from adult bone marrow has been proposed as a potential therapeutic approach for postinfarction left ventricular dysfunction. However, limited cell viability after transplantation into the myocardium has restricted its regenerative capacity. In this study, we genetically modified MSCs with an antiapoptotic Bcl-2 gene and evaluated cell survival, engraftment, revascularization, and functional improvement in a rat left anterior descending ligation model via intracardiac injection. Rat MSCs were manipulated to overexpress the Bcl-2 gene. In vitro, the antiapoptotic and paracrine effects were assessed under hypoxic conditions. In vivo, the Bcl-2 gene-modified MSCs (Bcl-2-MSCs) were injected after myocardial infarction. The surviving cells were tracked after transplantation. Capillary density was quantified after 3 weeks. The left ventricular function was evaluated by pressure-volume loops. The Bcl-2 gene protected MSCs against apoptosis. In vitro, Bcl-2 overexpression reduced MSC apoptosis by 32% and enhanced vascular endothelial growth factor secretion by more than 60% under hypoxic conditions. Transplantation with Bcl-2-MSCs increased 2.2-fold, 1.9-fold, and 1.2-fold of the cellular survival at 4 days, 3 weeks, and 6 weeks, respectively, compared with the vector-MSC group. Capillary density in the infarct border zone was 15% higher in Bcl-2-MSC transplanted animals than in vector-MSC treated animals. Furthermore, Bcl-2-MSC transplanted animals had 17% smaller infarct size than vector-MSC treated animals and exhibited functional recovery remarkably. Our current findings support the premise that transplantation of antiapoptotic gene-modified MSCs may have values for mediating substantial functional recovery after acute myocardial infarction.




This article has been cited by other articles:


Home page
Circ. Res.Home page
M. S. Penn and A. A. Mangi
Genetic Enhancement of Stem Cell Engraftment, Survival, and Efficacy
Circ. Res., June 20, 2008; 102(12): 1471 - 1482.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Y.-J. Yang, H.-Y. Qian, J. Huang, Y.-J. Geng, R.-L. Gao, K.-F. Dou, G.-S. Yang, J.-J. Li, R. Shen, Z.-X. He, et al.
Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts
Eur. Heart J., June 2, 2008; 29(12): 1578 - 1590.
[Abstract] [Full Text] [PDF]


Home page
Journal of Bioactive and Compatible PolymersHome page
A. Koc, N. Emin, A. E. Elcin, and Y. M. Elcin
In Vitro Osteogenic Differentiation of Rat Mesenchymal Stem Cells in a Microgravity Bioreactor
Journal of Bioactive and Compatible Polymers, May 1, 2008; 23(3): 244 - 261.
[Abstract] [PDF]


Home page
Stem CellsHome page
L. A. Mylotte, A. M. Duffy, M. Murphy, T. O'Brien, A. Samali, F. Barry, and E. Szegezdi
Metabolic Flexibility Permits Mesenchymal Stem Cell Survival in an Ischemic Environment
Stem Cells, May 1, 2008; 26(5): 1325 - 1336.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.peprotech.com/
Copyright © 2007 by AlphaMed Press.